IN2014CN04590A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04590A IN2014CN04590A IN4590CHN2014A IN2014CN04590A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A IN 4590CHN2014 A IN4590CHN2014 A IN 4590CHN2014A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A
- Authority
- IN
- India
- Prior art keywords
- nucleic acid
- acid strand
- nucleotides
- nucleotide analogs
- transcription product
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 abstract 9
- 150000007523 nucleic acids Chemical class 0.000 abstract 9
- 102000039446 nucleic acids Human genes 0.000 abstract 9
- 125000003729 nucleotide group Chemical group 0.000 abstract 7
- 239000002773 nucleotide Substances 0.000 abstract 4
- 238000013518 transcription Methods 0.000 abstract 3
- 230000035897 transcription Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 101710203526 Integrase Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011275488 | 2011-12-16 | ||
| PCT/JP2012/083180 WO2013089283A1 (en) | 2011-12-16 | 2012-12-17 | Chimeric double-stranded nucleic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04590A true IN2014CN04590A (cg-RX-API-DMAC7.html) | 2015-09-18 |
Family
ID=47559626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4590CHN2014 IN2014CN04590A (cg-RX-API-DMAC7.html) | 2011-12-16 | 2012-12-17 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9816089B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2791335B1 (cg-RX-API-DMAC7.html) |
| JP (7) | JP6112569B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104126010B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012353330B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3106312C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2707232T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014CN04590A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013089283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| CN104126010B (zh) * | 2011-12-16 | 2021-04-06 | 国立大学法人东京医科齿科大学 | 嵌合的双链核酸 |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| JP6440170B2 (ja) * | 2013-03-01 | 2018-12-19 | 国立大学法人 東京医科歯科大学 | キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤 |
| JP6300212B2 (ja) * | 2013-03-21 | 2018-03-28 | 国立大学法人 東京医科歯科大学 | 二重鎖核酸結合剤、当該結合剤−二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法 |
| AU2014282666A1 (en) * | 2013-06-16 | 2016-01-07 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| WO2015105083A1 (ja) * | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| JP6892433B2 (ja) | 2015-04-03 | 2021-06-23 | ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 十分に安定化された非対称ｓｉｒｎａ |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2017053999A1 (en) | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| US20180223280A1 (en) * | 2015-10-23 | 2018-08-09 | Rena Therapeutics Inc. | Nucleic acid complex |
| US20180228830A1 (en) * | 2015-10-23 | 2018-08-16 | Rena Therapeutics Inc. | Nucleic acid complex having at least one bulge structure |
| WO2017094745A1 (ja) * | 2015-12-01 | 2017-06-08 | 国立大学法人大阪大学 | 核酸を含む経腸投与用組成物 |
| AU2017211461B2 (en) * | 2016-01-26 | 2023-01-12 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| WO2018056442A1 (ja) * | 2016-09-23 | 2018-03-29 | 国立大学法人東京医科歯科大学 | 血液脳関門通過型ヘテロ２本鎖核酸 |
| WO2018062510A1 (ja) | 2016-09-29 | 2018-04-05 | 国立大学法人東京医科歯科大学 | オーバーハングを有する二本鎖核酸複合体 |
| CA3052801A1 (en) | 2017-02-06 | 2018-08-09 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11638717B2 (en) | 2017-03-29 | 2023-05-02 | Shionogi & Co., Ltd. | Complex of nucleic acid medicine and multibranched lipid |
| JP7141621B2 (ja) * | 2017-03-31 | 2022-09-26 | 学校法人 愛知医科大学 | コンドロイチン硫酸生合成を阻害するアンチセンス核酸 |
| JP6974872B2 (ja) * | 2017-06-30 | 2021-12-01 | 国立大学法人 東京医科歯科大学 | ヘテロ二本鎖型ａｎｔｉｍｉＲ |
| AU2018307294B2 (en) | 2017-07-26 | 2025-04-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| JP2021506239A (ja) | 2017-12-14 | 2021-02-22 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 複合アンチセンス化合物及びその使用 |
| WO2019167995A1 (ja) | 2018-02-28 | 2019-09-06 | 国立大学法人東京医科歯科大学 | 虚血病変部位特異的な遺伝子治療法 |
| WO2019181946A1 (ja) | 2018-03-19 | 2019-09-26 | 国立大学法人東京医科歯科大学 | 毒性が軽減した核酸 |
| WO2019182294A1 (ko) * | 2018-03-19 | 2019-09-26 | 주식회사 케이티 | 비디오 신호 처리 방법 및 장치 |
| AU2019237599A1 (en) | 2018-03-20 | 2020-11-12 | Nissan Chemical Corporation | Antisense oligonucleotide having reduced toxicity |
| EP3770257A4 (en) * | 2018-03-22 | 2022-03-09 | National University Corporation Tokyo Medical and Dental University | BHS-PASSING LIPID LIGAND OF A HETERONUCLEIC ACID |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| WO2020209285A1 (ja) | 2019-04-08 | 2020-10-15 | 国立大学法人東京医科歯科大学 | 筋疾患治療用医薬組成物 |
| EP4005602A4 (en) | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | NUCLEIC ACID AGENT TARGETED AGAINST MURF1 |
| US20240117346A1 (en) * | 2019-10-11 | 2024-04-11 | National University Corporation Tokyo Medical And Dental University | Modified hetero nucleic acids |
| EP4090744A4 (en) * | 2020-01-17 | 2024-04-10 | Anastasia Khvorova | UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS |
| CA3169474A1 (en) | 2020-01-31 | 2021-08-05 | Sanwa Kagaku Kenkyusho Co., Ltd. | Antisense oligonucleotide of atn1 |
| JPWO2021177418A1 (cg-RX-API-DMAC7.html) | 2020-03-04 | 2021-09-10 | ||
| JPWO2021187392A1 (cg-RX-API-DMAC7.html) * | 2020-03-16 | 2021-09-23 | ||
| CN115968374A (zh) | 2020-06-15 | 2023-04-14 | Liid制药股份有限公司 | 交联型核苷及核苷酸 |
| US20240002853A1 (en) | 2020-11-23 | 2024-01-04 | Alpha Anomeric Sas | Nucleic acid duplexes |
| WO2022183102A1 (en) * | 2021-02-26 | 2022-09-01 | Northwestern University | Cell-free biosensors with dna strand displacement circuits |
| EP4349986A4 (en) | 2021-05-25 | 2025-11-19 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ???? |
| CN117412773A (zh) | 2021-05-31 | 2024-01-16 | 瑞纳治疗公司 | 配体结合核酸复合物 |
| JPWO2023022229A1 (cg-RX-API-DMAC7.html) * | 2021-08-19 | 2023-02-23 | ||
| EP4389893A4 (en) | 2021-08-21 | 2025-09-10 | Takeda Pharmaceuticals Co | PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR |
| US20250179486A1 (en) | 2021-09-15 | 2025-06-05 | National University Corporation Tokyo Medical And Dental University | Heteronucleic acid including 2'-modified nucleoside |
| WO2023064937A1 (en) * | 2021-10-14 | 2023-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Programmable delivery platforms for rna structures |
| JPWO2023080159A1 (cg-RX-API-DMAC7.html) | 2021-11-02 | 2023-05-11 | ||
| US20250297249A1 (en) | 2021-12-07 | 2025-09-25 | Liid Pharmaceuticals, Inc. | Antisense oligonucleotide complex |
| WO2024071099A1 (ja) | 2022-09-29 | 2024-04-04 | 国立大学法人東京医科歯科大学 | ５'－シクロプロピレン修飾を含む核酸分子 |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024228398A1 (ja) * | 2023-05-02 | 2024-11-07 | 国立大学法人東京医科歯科大学 | グアニン四重鎖構造を誘導するための核酸剤 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09110894A (ja) * | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤 |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3781879B2 (ja) | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US20060074034A1 (en) * | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| AU2002249967A1 (en) | 2001-11-12 | 2003-05-26 | Epiclone, Inc. | Gene silencing using sense dna and antisense rna hybrid constructs |
| WO2004003134A2 (en) * | 2002-06-26 | 2004-01-08 | Isis Pharmaceuticals, Inc. | Antisense inhibition via rnase h-independent reduction in mrna |
| DE10240417A1 (de) | 2002-09-02 | 2004-03-11 | Avontec Gmbh | Decoy-Oligonukleotid-Hemmung der CD40-Expression |
| AU2003273336A1 (en) * | 2002-09-18 | 2004-04-08 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna's by single- and double-stranded oligomeric compounds |
| EP2336318B1 (en) * | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
| US7427672B2 (en) | 2003-08-28 | 2008-09-23 | Takeshi Imanishi | Artificial nucleic acids of n-o bond crosslinkage type |
| CN100558893C (zh) * | 2003-09-18 | 2009-11-11 | Isis药物公司 | eIF4E表达的调节 |
| US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| AU2011204898A1 (en) * | 2004-04-09 | 2011-08-11 | Biodelivery Sciences International, Inc | Nucleotide-cochleate compositions and methods of use |
| US20080199960A1 (en) * | 2004-05-13 | 2008-08-21 | Juliano Rudolph L | Methods for the Delivery of Oligomeric Compounds |
| WO2006074108A2 (en) * | 2004-12-30 | 2006-07-13 | Hauser Todd M | Compositions and methods for modulating gene expression using self-protected oligonucleotides |
| EP2015758B1 (en) | 2006-05-05 | 2014-04-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
| US8673548B2 (en) | 2006-08-10 | 2014-03-18 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
| EP2076597A2 (en) | 2006-10-09 | 2009-07-08 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US7858592B2 (en) * | 2007-02-26 | 2010-12-28 | The Board Of Regents Of The University Of Texas System | Interfering RNAs against the promoter region of P53 |
| WO2008111908A1 (en) * | 2007-03-15 | 2008-09-18 | Jyoti Chattopadhyaya | Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer |
| NZ587178A (en) * | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2133425A1 (en) * | 2008-06-13 | 2009-12-16 | Karin Mölling | Method and compound for antiviral (HIV) therapy |
| US8541569B2 (en) * | 2008-09-06 | 2013-09-24 | Chemgenes Corporation | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA |
| DK3252068T3 (da) * | 2009-10-12 | 2025-08-25 | Larry J Smith | Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro |
| CN104126010B (zh) | 2011-12-16 | 2021-04-06 | 国立大学法人东京医科齿科大学 | 嵌合的双链核酸 |
| EP3004347B1 (en) * | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
-
2012
- 2012-12-17 CN CN201280062110.XA patent/CN104126010B/zh active Active
- 2012-12-17 AU AU2012353330A patent/AU2012353330B2/en active Active
- 2012-12-17 EP EP12815856.5A patent/EP2791335B1/en active Active
- 2012-12-17 IN IN4590CHN2014 patent/IN2014CN04590A/en unknown
- 2012-12-17 CA CA3106312A patent/CA3106312C/en active Active
- 2012-12-17 WO PCT/JP2012/083180 patent/WO2013089283A1/en not_active Ceased
- 2012-12-17 JP JP2014528740A patent/JP6112569B2/ja active Active
- 2012-12-17 CN CN202011292547.5A patent/CN112386605A/zh active Pending
- 2012-12-17 CA CA2859581A patent/CA2859581C/en active Active
- 2012-12-17 ES ES12815856T patent/ES2707232T3/es active Active
-
2014
- 2014-06-13 US US14/303,989 patent/US9816089B2/en active Active
-
2017
- 2017-03-08 JP JP2017044034A patent/JP6416301B2/ja active Active
- 2017-10-05 US US15/725,845 patent/US10337006B2/en active Active
-
2018
- 2018-06-28 US US16/021,165 patent/US10329567B2/en active Active
- 2018-10-03 JP JP2018188022A patent/JP6638923B2/ja active Active
-
2019
- 2019-05-13 US US16/410,803 patent/US11034955B2/en active Active
- 2019-12-12 JP JP2019224279A patent/JP6960123B2/ja active Active
-
2020
- 2020-10-27 JP JP2020179738A patent/JP7174384B2/ja active Active
-
2021
- 2021-05-27 US US17/332,249 patent/US12344841B2/en active Active
- 2021-08-24 JP JP2021136038A patent/JP2022000426A/ja active Pending
-
2022
- 2022-09-15 JP JP2022146970A patent/JP7423015B2/ja active Active
-
2023
- 2023-12-21 US US18/392,869 patent/US20240158790A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04590A (cg-RX-API-DMAC7.html) | ||
| Martens-Uzunova et al. | Beyond microRNA–novel RNAs derived from small non-coding RNA and their implication in cancer | |
| HK1221978A1 (zh) | Tmprss6 irna组合物及其使用方法 | |
| IN2013MN00522A (cg-RX-API-DMAC7.html) | ||
| EP2580355A4 (en) | A REVERSE TRANSCRIPTION AND THROUGH BASE-SPACING RESTRICTED QUANTITATIVE PCR PROVIDED THROUGH AN OLIGONUCLEOTIDE WITH A CHANGED HAIR NEEDLE STRUCTURE | |
| EP3693464A3 (en) | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes | |
| WO2010080129A3 (en) | Extended dicer substrate agents and methods for the specific inhibition of gene expression | |
| NZ593618A (en) | Gnaq targeted dsrna compositions and methods for inhibiting expression | |
| NZ627060A (en) | Polynucleotide molecules for gene regulation in plants | |
| WO2011123621A3 (en) | 2' and 5' modified monomers and oligonucleotides | |
| WO2012142611A3 (en) | Sequencing small amounts of complex nucleic acids | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| SG10201804076RA (en) | Methods for multiplex detection of alleles associated with ophthalmic conditions | |
| NZ601247A (en) | Targeted genomic alteration | |
| JP2012050447A5 (cg-RX-API-DMAC7.html) | ||
| WO2012168307A3 (en) | Improved recombination efficiency by inhibition of nhej dna repair | |
| WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
| WO2012178033A3 (en) | Serpina1 sirnas: compositions of matter and methods of treatment | |
| WO2012115454A3 (ko) | 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법 | |
| WO2012177949A3 (en) | Compositions and methods for inhibition of expression of protein c (proc) genes | |
| WO2007147067A8 (en) | Methods and compositions for regulating cell cycle progression | |
| Cortez et al. | microRNAs in cancer: from bench to bedside | |
| WO2009086428A3 (en) | Methods and compositions for increasing gene expression | |
| MX2019009305A (es) | Oligonucleotido de cadena simple. | |
| WO2013040393A3 (en) | Genes contributing to survival of cancer cells |